Scott Moomaw Sells 18,314 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) insider Scott Moomaw sold 18,314 shares of the firm’s stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $36.79, for a total transaction of $673,772.06. Following the sale, the insider owned 187,640 shares in the company, valued at approximately $6,903,275.60. This represents a 8.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Scott Moomaw also recently made the following trade(s):

• On Monday, January 12th, Scott Moomaw sold 20,533 shares of Liquidia stock. The stock was sold at an average price of $37.43, for a total transaction of $768,550.19.

Liquidia Price Performance

NASDAQ:LQDA opened at $36.77 on Friday. Liquidia Corporation has a 52 week low of $11.26 and a 52 week high of $46.67. The company has a quick ratio of 1.84, a current ratio of 2.01 and a debt-to-equity ratio of 2.97. The stock has a market capitalization of $3.24 billion, a PE ratio of -44.30 and a beta of 0.52. The stock’s 50-day moving average price is $37.70 and its 200-day moving average price is $31.77.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings results on Thursday, March 5th. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.07. The firm had revenue of $92.02 million during the quarter, compared to analyst estimates of $87.49 million. Liquidia had a negative return on equity of 209.33% and a negative net margin of 43.53%.The business’s quarterly revenue was up 3072.4% on a year-over-year basis. As a group, equities analysts expect that Liquidia Corporation will post -1.51 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on LQDA shares. Zacks Research downgraded Liquidia from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 27th. Needham & Company LLC boosted their price target on shares of Liquidia from $52.00 to $54.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. BTIG Research upped their price objective on shares of Liquidia from $49.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Wall Street Zen raised shares of Liquidia from a “hold” rating to a “buy” rating in a report on Saturday, March 7th. Finally, Wells Fargo & Company lifted their target price on shares of Liquidia from $44.00 to $51.00 and gave the company an “overweight” rating in a research report on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $43.44.

Institutional Trading of Liquidia

Several institutional investors have recently made changes to their positions in the company. Farallon Capital Management LLC grew its position in Liquidia by 102.1% in the third quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock worth $194,783,000 after acquiring an additional 4,326,876 shares during the period. TCG Crossover Management LLC purchased a new stake in Liquidia during the third quarter worth about $38,887,000. Caprock Group LLC acquired a new position in shares of Liquidia in the third quarter valued at approximately $37,114,000. MPM Bioimpact LLC boosted its position in Liquidia by 600.4% in the 4th quarter. MPM Bioimpact LLC now owns 1,400,869 shares of the company’s stock valued at $48,316,000 after buying an additional 1,200,869 shares during the period. Finally, Voloridge Investment Management LLC acquired a new position in shares of Liquidia in the third quarter worth $12,571,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).